甲磺酸萘莫司他的体外抗凝研究进展  

Research progress of in vitro anticoagulation of nafamostat mesylate

作　　者：宁立娟 杨发奋[1] 谭军华[1] NING Lijuan;YANG Fafen;TAN Junhua(Affiliated Hospital of Youjiang Medical University for Nationalities,Baise 533000;Graduate School,Youjiang Medical University for Nationalities,Baise 533000,China)

机构地区：[1]右江民族医学院附属医院,广西百色533000 [2]右江民族医学院研究生学院,广西百色533000

出　　处：《临床医学研究与实践》2024年第4期191-194,共4页Clinical Research and Practice

基　　金：广西骨与关节退行性疾病基础研究与转化重点实验室2022年度开放课题[No.21-220-06(202209)]。

摘　　要：体外抗凝是血液在体外循环时加入抗凝剂,防止血液在管路及过滤器中发生凝血。抗凝剂的选择是体外抗凝顺利实施的重要环节。目前所使用的抗凝剂如肝素、低分子量肝素(LMWH)、枸橼酸等,但并不适用于高危患者,易发生出血、血栓等并发症,不易掌握。甲磺酸萘莫司他(NM)作为新型抗凝药物,在国外许多临床实验已证实了其具有适应症广、并发症少等优点,但在我国抗凝方面的研究报道较少。现就NM在体外抗凝的临床应用进展进行综述。In vitro anticoagulation is the addition of blood anticoagulant in the extracorporeal circulation to prevent blood coagulation in the tubing and filters.The selection of anticoagulant is an important part of the smooth implementation of in vitro anticoagulation.The current anticoagulants,such as heparin,low molecular weight heparin(LMWH),citrate,etc.,are not suitable for high-risk patients,and are prone to bleeding,thrombosis and other complications,which are not easy to master.As a new anticoagulant,nafamostat mesilate(NM)has the advantages of wide indications and fewer complications in many clinical experiments abroad,but there are few reports on NM in anticoagulation in China.This article reviews the clinical application of NM in vitro anticoagulation.

关 键 词：甲磺酸萘莫司他 体外抗凝 抗凝剂 

分 类 号：R459.5[医药卫生—治疗学]